Monday, May 26, 2014
BioCentury's 12th annual
European Iceberg survey projects one of the lowest financing demand figures
ever for public biotechs, thanks to the robust funding environment over the
last two years. But while private companies actually raised a record amount of
cash in 2013, the appetite for capital in this group increased due to the
ballooning cohort of Phase II companies.
The Iceberg survey aims to
identify the underlying demand for finance by private and public biotechs in
Europe, including Israel, over the next three years. The survey includes only
companies that have reached the clinic or the market. It excludes profitable
publicly traded biotechs.